Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Oscar G. Arrieta et al. · The Lancet · 2014

Cited by 1,306 works. doi:10.1016/s0140-6736(14)60845-x

Authors

References